NS Pharma, a subsidiary of Nippon Shinyaku Co., announced that acceptance has been received by Capricor Therapeutics (CAPR) from the U.S. FDA ...
The FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Japan’s NS Pharma takes on Sarepta and its controversially approved rival. NS Pharma ...
The Japanese group’s NS Pharma subsidiary has revealed that Viltepso (viltolarsen) missed its primary objective in the confirmatory RACER53 trial, and was unable to distinguish itself from ...
QNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments ...
TEL AVIV, Israel, Feb. 27, 2025 /PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based ...
Solara Active Pharma Sciences Ltd (BOM:541540) reports significant financial growth and strategic advancements despite ongoing challenges. Over the past week, the Indian market has remained flat ...